Last reviewed · How we verify
UMEC/VI DPI
UMEC/VI is a combination of umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta-2 agonist) that relaxes airway smooth muscle and improves airflow in chronic obstructive pulmonary disease.
UMEC/VI is a combination of umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta-2 agonist) that relaxes airway smooth muscle and improves airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | UMEC/VI DPI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) |
| Target | Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Umeclidinium blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, promoting smooth muscle relaxation and bronchodilation. Together, these complementary mechanisms provide sustained bronchodilation over 24 hours.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Tachycardia
- Dry mouth
- Urinary retention
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design (PHASE4)
- Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UMEC/VI DPI CI brief — competitive landscape report
- UMEC/VI DPI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI